perillyl alcohol has been researched along with dacarbazine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G | 1 |
| Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T | 1 |
| Barath, M; Chen, TC; Cho, HY; Hofman, FM; Schönthal, AH; Sharma, N; Wang, W | 1 |
| Chen, TC; Guo, W; Li, Y; Lv, L; Song, X; Wang, W; Wang, X; Wei, L; Xie, L | 1 |
| Chen, TC; Song, X; Wang, W; Wang, X; Xie, L; Zeng, Q | 1 |
1 trial(s) available for perillyl alcohol and dacarbazine
| Article | Year |
|---|---|
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Monoterpenes; Neoplasm Recurrence, Local; Oncogene Protein p21(ras); Signal Transduction; Survival Rate; Temozolomide; Transforming Growth Factor beta; Treatment Outcome | 2008 |
4 other study(ies) available for perillyl alcohol and dacarbazine
| Article | Year |
|---|---|
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytokines; Dacarbazine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glioma; Humans; Mice; Monoterpenes; Nelfinavir; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA Modification Methylases; DNA Repair Enzymes; Drug Combinations; Drug Resistance, Neoplasm; Humans; Mice; Monoterpenes; Temozolomide; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
Therapeutic effect of TMZ-POH on human nasopharyngeal carcinoma depends on reactive oxygen species accumulation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Enzyme Activation; Female; G2 Phase Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Monoterpenes; Nasopharyngeal Neoplasms; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Temozolomide-perillyl alcohol conjugate induced reactive oxygen species accumulation contributes to its cytotoxicity against non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Monoterpenes; Reactive Oxygen Species; Temozolomide | 2016 |